Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · §3

Draft synthesis: Percentage weight change as a surrogate… — disposition

The disposition of every submission and the amendments that resulted.

Document identifier
CEI-CP-111/3
Series
Public comment period
Version
1.0
Published
03 Jun 2025
Last reviewed
03 Jun 2025
Next review
03 Jun 2026
Identifier
10.71829/cei.cp.111
Certainty
Not rated
Cycle
2025 Q2
Window
28 Apr 2025 – 26 May 2025
Status
Closed
Submissions
9

§3Disposition and amendments

§3.1Disposition table

Table 1. Every submission with its disposition. Each row links to the submission in full.

ReferenceRespondentPoint raisedDisposition
DRAFT-SURROGATE-OU/009Dr Jolyon Grünbaum-SowandeRegistered trials that never reported are not counted anywhere in the reviewAccepted
DRAFT-SURROGATE-OU/001Dr Amara QuaresmaDeclared interests should appear on the document rather than on a separate pageNoted, no amendment
DRAFT-SURROGATE-OU/002Yusuf Whitmarsh-ObiThe choice of effect measure is not justified and changes the appearance of the resultAccepted in part
DRAFT-SURROGATE-OU/004Quentin Gwynne-SarpongSubgroup findings are reported that were not registered in the protocolAccepted in part
DRAFT-SURROGATE-OU/007Dr Lorcan Zaleski-MbekiIntention-to-treat and efficacy-estimand results are combined without distinctionAccepted
DRAFT-SURROGATE-OU/003Dr Wolfram Kaltenbach-MensahThe conclusion is stated more strongly than the certainty rating supportsAccepted
DRAFT-SURROGATE-OU/008Dr Katarzyna YorkstonePoint estimates are given without an intervalAccepted in part
DRAFT-SURROGATE-OU/005Dr Jacinta Steenkamp-FerreiraResults at materially different follow-up durations are pooledAccepted
DRAFT-SURROGATE-OU/006Dr Mordecai Bellingham-OjoThe document should state what a reader ought to doNot accepted
9 submissions in total.

§3.2Summary by disposition

Table 2. Counts by disposition, with the meaning of each.

DispositionCountMeaning
Accepted4The submission is accepted and the draft is amended as proposed. The amendment is recorded in the amendment log of the document it changed and is traceable to the numbered submission.
Accepted in part3Part of the submission is accepted and part is not. The secretariat response states which part is which and on what ground the remainder was declined.
Noted, no amendment1The submission raises a point the Institute accepts but that does not require a change to the draft, most often because the draft already states it elsewhere. The location is given in the response.
Not accepted1The submission is not accepted. The secretariat response gives the reason. A submission that is not accepted remains published in full; the Institute does not remove a submission because it disagrees with it.

§3.3Resulting amendments

  1. Registered trials that never reported are not counted anywhere in the review — arising from DRAFT-SURROGATE-OU/009. Registered trials without posted results are now identified, counted and reported as a distinct category in the screening flow, with the proportion of registered participants they represent stated in the limitations.
  2. The choice of effect measure is not justified and changes the appearance of the result — arising from DRAFT-SURROGATE-OU/002. Every outcome now reports the relative effect and, where an assumed baseline risk can be stated and sourced, the corresponding absolute effect, with the baseline risk and its source given in the same row.
  3. Subgroup findings are reported that were not registered in the protocol — arising from DRAFT-SURROGATE-OU/004. Every subgroup analysis is now labelled as pre-specified or post hoc against the registered protocol, post hoc analyses are reported in a separate subsection without a certainty rating, and the protocol version against which the labelling was made is stated.
  4. Intention-to-treat and efficacy-estimand results are combined without distinction — arising from DRAFT-SURROGATE-OU/007. The treatment-policy estimand is used throughout as the primary analysis, the efficacy estimand is reported as a secondary analysis where available, and the estimand used is stated in every row of the summary of findings.
  5. The conclusion is stated more strongly than the certainty rating supports — arising from DRAFT-SURROGATE-OU/003. Conclusion wording is now drawn from a fixed set of formulations tied to the certainty rating, so that a low certainty rating produces a statement that the evidence may suggest an effect and that the estimate is likely to change with further research.
  6. Point estimates are given without an interval — arising from DRAFT-SURROGATE-OU/008. Every estimate now carries its interval where the source reported one, and where it did not, the estimate is annotated as reported without an interval rather than left to appear as a precise figure.
  7. Results at materially different follow-up durations are pooled — arising from DRAFT-SURROGATE-OU/005. Estimates are now reported by duration band, with the number of contributing trials and participants in each band stated, and no estimate is pooled across bands.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.